Z
ZyVersa Therapeutics D
D
ZVSA
1.09000
USD
-0.03
(-2.68%)
Market Open
Volume
1,777
EPS
0
Div Yield
0
P/E
0
Market Cap
1,170,874
Novo Nordisk Surges in Profit and Sales
6 months ago
Stocks news More
Title: ZyVersa Therapeutics
Sector: Healthcare
Industry: Biotechnology
ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.